NFIC

Across TCGA pan-cancer cohorts, NFIC Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NFIC data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in pheochromocytoma and paraganglioma (PCPG), where higher NFIC Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NFIC expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

PCPG, UCEC, and SKCM are the cancer types where NFIC Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PCPG	OS	Median	All	0.032	0.948	<.001	12	view →
UCEC	DFS	Median	All	1.000	0.630	.029	6	view →
SKCM	DFS	Median	II,III,IV	1.000	0.559	.022	4	view →
LUAD	DFS	Median	All	0.206	0.767	.006	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NFIC–PCPG (OS)

Open the PCPG breakdown →